.png){kind=icon}
Return
Ethical Issues Surrounding Newborn Screening
.png){kind=icon}
OA
AI
DOI：10.3390/ijns7010003.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
It would be difficult to overestimate the importance of persistent, thoughtful parents and their importance in the development of treatments for their children's rare disorders. Almost a century ago in Norway, observant parents led a brilliant young physician-scientist to his discovery of the underlying cause of their children's profound developmental delay-i.e., phenylketonuria, or PKU. Decades later, in a recovering war-ravaged Britain, an equally persistent mother pressed the scientists at Birmingham Children's Hospital to find a way to treat her seriously damaged daughter, Sheila, who suffered from PKU. Living on the financial edge, this mother insisted that Bickel and colleagues develop such a diet, and she volunteered Sheila to be the patient in the trial. The scientists concluded that the low phenylalanine diet helped but needed to be started very early-so, newborn screening was born to permit the implementation of this. Many steps brought us to where we are today, but these courageous parents made it all begin.
Keywords:
parental advocacy history
residual dried blood spots
newborn screening expansion
recommended uniform screening panel (RUSP)
secretary's advisory committee of heritable disorders in newborns and children (ACHDNC)
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
I
IF:
4
Papers:
685
Citations:
1.4K
Organization
Cited Papers
.png){kind=icon}
ShareSaveShareSaveShareSave
View more